论文部分内容阅读
目的观察沙美特罗替卡松粉吸入剂治疗中重度持续支气管哮喘的疗效。方法 118例患者吸入沙美特罗替卡松粉,自身对照观察患者6个月内症状改善、急诊就医次数、治疗开始及第1、3、6个月后第1秒钟用力呼气容积(FEV_1)占预计值百分比(FEV_1%)、最大呼气流速(PEF),记录哮喘控制得分(ACT)。结果治疗后PEF均有显著增加,第1个月增加30.8%,第3个月增加43.4%,第6个月增加54.1%,与治疗前比较均有显著性差异(q=13.56,P<0.01;q=16.25,P<0.01;q=19.23,P<0.01)。治疗半年后,无症状天数明显增加、急诊就医次数减少、患者哮喘生命质量评分明显提高。结论沙美特罗替卡松粉吸入剂能够控制大多数成人中重度哮喘患者的症状,改善肺功能和生活质量,具有良好的依从性和安全性。
Objective To observe the efficacy of salmeterol and fluticasone powder inhaler in the treatment of moderate and severe bronchial asthma. Methods One hundred and eighteen patients were challenged with salmeterol and fluticasone propionate, and their symptoms were observed within 6 months in their own control. The number of emergency medical visits, the beginning of treatment and the forced expiratory volume at 1 second (FEV_1 ) As a percentage of predicted (FEV_1%), maximum expiratory flow (PEF), and recorded asthma control score (ACT). Results After treatment, the PEF was significantly increased in the first month increased 30.8%, the third month increased 43.4%, the first 6 months increased 54.1%, compared with before treatment were significantly different (q = 13.56, P <0.01 ; q = 16.25, P <0.01; q = 19.23, P <0.01). Six months after treatment, the number of asymptomatic days was significantly increased, the number of emergency medical visits decreased, patients’ asthma quality of life scores were significantly improved. Conclusion Salmeterol truss powder inhalation can control the symptoms of most adult patients with moderate and severe asthma, improve lung function and quality of life, with good compliance and safety.